Bayer Said to Explore Sale of $1.1 Billion Dermatology Business

  • German drugmaker working with JPMorgan on potential disposal
  • Bayer considering sale as it pursues Monsanto acquisition

Bayer AG is exploring the sale of its dermatology business, according to people familiar with the matter, as the German drugmaker gets rid of peripheral enterprises and pursues the takeover of crop chemicals rival Monsanto Co.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.